An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.
Identifieur interne : 000119 ( PubMed/Checkpoint ); précédent : 000118; suivant : 000120An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.
Auteurs : Kawsar R. Talaat [États-Unis] ; Ruth A. Karron ; Philana H. Liang ; Bridget A. Mcmahon ; Catherine J. Luke ; Bhagvanji Thumar ; Grace L. Chen ; Ji-Young Min ; Elaine W. Lamirande ; Hong Jin ; Kathy L. Coelingh ; George W. Kemble ; Kanta SubbaraoSource :
- Influenza and other respiratory viruses [ 1750-2659 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte, Anticorps antiviraux (sang), Excrétion virale, Femelle, Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Jeune adulte, Mâle, Réplication virale, Résultat thérapeutique, Sous-type H2N2 du virus de la grippe A (génétique), Sous-type H2N2 du virus de la grippe A (immunologie), Sous-type H2N2 du virus de la grippe A (isolement et purification), Sous-type H2N2 du virus de la grippe A (physiologie), Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins atténués (administration et posologie), Vaccins atténués (effets indésirables), Vaccins atténués (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins atténués.
- effets indésirables : Vaccins antigrippaux, Vaccins atténués.
- génétique : Sous-type H2N2 du virus de la grippe A.
- immunologie : Grippe humaine, Sous-type H2N2 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués.
- isolement et purification : Sous-type H2N2 du virus de la grippe A.
- physiologie : Sous-type H2N2 du virus de la grippe A.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine.
- Adulte, Excrétion virale, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Réplication virale, Résultat thérapeutique, Vaccination.
English descriptors
- KwdEn :
- Adult, Antibodies, Viral (blood), Female, Humans, Influenza A Virus, H2N2 Subtype (genetics), Influenza A Virus, H2N2 Subtype (immunology), Influenza A Virus, H2N2 Subtype (isolation & purification), Influenza A Virus, H2N2 Subtype (physiology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Treatment Outcome, Vaccination, Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (immunology), Virus Replication, Virus Shedding, Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Vaccines, Attenuated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- chemical , blood : Antibodies, Viral.
- genetics : Influenza A Virus, H2N2 Subtype.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza Vaccines, Influenza, Human, Vaccines, Attenuated.
- isolation & purification : Influenza A Virus, H2N2 Subtype.
- physiology : Influenza A Virus, H2N2 Subtype.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adult, Female, Humans, Male, Treatment Outcome, Vaccination, Virus Replication, Virus Shedding, Young Adult.
Abstract
Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine.
DOI: 10.1111/j.1750-2659.2012.00350.x
PubMed: 22417012
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22417012Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.</title><author><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R" last="Talaat">Kawsar R. Talaat</name><affiliation wicri:level="1"><nlm:affiliation>Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A" last="Karron">Ruth A. Karron</name></author><author><name sortKey="Liang, Philana H" sort="Liang, Philana H" uniqKey="Liang P" first="Philana H" last="Liang">Philana H. Liang</name></author><author><name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A" last="Mcmahon">Bridget A. Mcmahon</name></author><author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name></author><author><name sortKey="Thumar, Bhagvanji" sort="Thumar, Bhagvanji" uniqKey="Thumar B" first="Bhagvanji" last="Thumar">Bhagvanji Thumar</name></author><author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name></author><author><name sortKey="Min, Ji Young" sort="Min, Ji Young" uniqKey="Min J" first="Ji-Young" last="Min">Ji-Young Min</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name></author><author><name sortKey="Coelingh, Kathy L" sort="Coelingh, Kathy L" uniqKey="Coelingh K" first="Kathy L" last="Coelingh">Kathy L. Coelingh</name></author><author><name sortKey="Kemble, George W" sort="Kemble, George W" uniqKey="Kemble G" first="George W" last="Kemble">George W. Kemble</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22417012</idno><idno type="pmid">22417012</idno><idno type="doi">10.1111/j.1750-2659.2012.00350.x</idno><idno type="wicri:Area/PubMed/Corpus">000148</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000148</idno><idno type="wicri:Area/PubMed/Curation">000148</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000148</idno><idno type="wicri:Area/PubMed/Checkpoint">000119</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.</title><author><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R" last="Talaat">Kawsar R. Talaat</name><affiliation wicri:level="1"><nlm:affiliation>Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A" last="Karron">Ruth A. Karron</name></author><author><name sortKey="Liang, Philana H" sort="Liang, Philana H" uniqKey="Liang P" first="Philana H" last="Liang">Philana H. Liang</name></author><author><name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A" last="Mcmahon">Bridget A. Mcmahon</name></author><author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name></author><author><name sortKey="Thumar, Bhagvanji" sort="Thumar, Bhagvanji" uniqKey="Thumar B" first="Bhagvanji" last="Thumar">Bhagvanji Thumar</name></author><author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name></author><author><name sortKey="Min, Ji Young" sort="Min, Ji Young" uniqKey="Min J" first="Ji-Young" last="Min">Ji-Young Min</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name></author><author><name sortKey="Coelingh, Kathy L" sort="Coelingh, Kathy L" uniqKey="Coelingh K" first="Kathy L" last="Coelingh">Kathy L. Coelingh</name></author><author><name sortKey="Kemble, George W" sort="Kemble, George W" uniqKey="Kemble G" first="George W" last="Kemble">George W. Kemble</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></analytic><series><title level="j">Influenza and other respiratory viruses</title><idno type="eISSN">1750-2659</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Humans</term><term>Influenza A Virus, H2N2 Subtype (genetics)</term><term>Influenza A Virus, H2N2 Subtype (immunology)</term><term>Influenza A Virus, H2N2 Subtype (isolation & purification)</term><term>Influenza A Virus, H2N2 Subtype (physiology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Treatment Outcome</term><term>Vaccination</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (adverse effects)</term><term>Vaccines, Attenuated (immunology)</term><term>Virus Replication</term><term>Virus Shedding</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Anticorps antiviraux (sang)</term><term>Excrétion virale</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Réplication virale</term><term>Résultat thérapeutique</term><term>Sous-type H2N2 du virus de la grippe A (génétique)</term><term>Sous-type H2N2 du virus de la grippe A (immunologie)</term><term>Sous-type H2N2 du virus de la grippe A (isolement et purification)</term><term>Sous-type H2N2 du virus de la grippe A (physiologie)</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (effets indésirables)</term><term>Vaccins atténués (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza Vaccines</term><term>Influenza, Human</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term><term>Vaccination</term><term>Virus Replication</term><term>Virus Shedding</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Excrétion virale</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Réplication virale</term><term>Résultat thérapeutique</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22417012</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.</ArticleTitle><Pagination><MedlinePgn>66-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1750-2659.2012.00350.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Live attenuated influenza vaccines (LAIV) against a variety of strains of pandemic potential are being developed and tested. We describe the results of an open-label phase I trial of a live attenuated H2N2 virus vaccine.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the safety, infectivity, and immunogenicity of a live attenuated H2N2 influenza virus vaccine.</AbstractText><AbstractText Label="PARTICIPANTS/METHODS" NlmCategory="METHODS">The A/Ann Arbor/6/60 (H2N2) virus used in this study is the attenuated, cold-adapted, temperature-sensitive strain that provides the genetic backbone of seasonal LAIV (MedImmune). We evaluated the safety, infectivity, and immunogenicity of two doses of 10(7) TCID(50) of this vaccine administered by nasal spray 4 weeks apart to normal healthy seronegative adults.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-one participants received a first dose of the vaccine; 18 participants received a second dose. No serious adverse events occurred during the trial. The most common adverse events after vaccination were headache and musculoskeletal pain. The vaccine was restricted in replication: 24% and 17% had virus detectable by culture or rRT-PCR after the first and second dose, respectively. Antibody responses to the vaccine were also restricted: 24% of participants developed an antibody response as measured by either hemagglutination-inhibition assay (10%), or ELISA for H2 HA-specific serum IgG (24%) or IgA (16%) after either one or two doses. None of the participants had a neutralizing antibody response. Vaccine-specific IgG-secreting cells as measured by enzyme-linked immunospot increased from a mean of 0·5 to 2·0/10(6) peripheral blood mononuclear cells (PBMCs); vaccine-specific IgA-secreting cells increased from 0·1 to 0·5/10(6) PBMCs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The live attenuated H2N2 1960 AA ca vaccine demonstrated a safety profile consistent with seasonal trivalent LAIV but was restricted in replication and minimally immunogenic in healthy seronegative adults.</AbstractText><CopyrightInformation>Published 2012. This article is a US Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talaat</LastName><ForeName>Kawsar R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karron</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Philana H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Bridget A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Luke</LastName><ForeName>Catherine J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Thumar</LastName><ForeName>Bhagvanji</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Grace L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Ji-Young</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Coelingh</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Kemble</LastName><ForeName>George W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 AI015444</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId><ArticleId IdType="doi">10.1111/j.1750-2659.2012.00350.x</ArticleId><ArticleId IdType="pmc">PMC3527634</ArticleId><ArticleId IdType="mid">NIHMS355684</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2007 Feb 15;356(7):685-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17301299</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2004 Dec;3(6):643-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15606348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2000 Mar;181(3):1133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10720541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 2011 Jun;72(6):463-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21414368</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Mar 1;199(5):711-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19210163</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2008 Aug 1;47(3):401-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18558875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2003 Jul;41(7):3133-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12843053</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2011 Mar;5(2):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">21306569</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2007 Apr;7(4):267-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17363960</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1985 Oct;95(2):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">4067301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2005 Jun;5(6):332</Citation><ArticleIdList><ArticleId IdType="pubmed">15948311</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1980 Aug;29(2):342-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7011972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1989 Nov;63(11):4603-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2795713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1999 Apr;37(4):937-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10074505</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1978 Jun 1;87(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">664248</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Jul 14;282(2):137-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10411194</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Sep;3(5):233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21462400</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Aug 12;26(34):4299-303</Citation><ArticleIdList><ArticleId IdType="pubmed">18582523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Assoc. 1958 Mar 8;166(10):1140-8</Citation><ArticleIdList><ArticleId IdType="pubmed">13513331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2006 Mar;132(1-2):113-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16271401</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Feb 11;27(7):1101-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19095024</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1983 Jun;40(3):1044-51</Citation><ArticleIdList><ArticleId IdType="pubmed">6852910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1967 Feb 11;213(5076):612-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Jan 31;20(9-10):1340-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11818152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Nov 22;362(9397):1733-45</Citation><ArticleIdList><ArticleId IdType="pubmed">14643124</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1973 Jan;7(1):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16558072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(1):215-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17050593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 8;27(28):3744-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19464558</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Respir Crit Care Med. 2007 Apr;28(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17458770</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2006 Dec;12(12):1997-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17354343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name><name sortKey="Coelingh, Kathy L" sort="Coelingh, Kathy L" uniqKey="Coelingh K" first="Kathy L" last="Coelingh">Kathy L. Coelingh</name><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><name sortKey="Karron, Ruth A" sort="Karron, Ruth A" uniqKey="Karron R" first="Ruth A" last="Karron">Ruth A. Karron</name><name sortKey="Kemble, George W" sort="Kemble, George W" uniqKey="Kemble G" first="George W" last="Kemble">George W. Kemble</name><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name><name sortKey="Liang, Philana H" sort="Liang, Philana H" uniqKey="Liang P" first="Philana H" last="Liang">Philana H. Liang</name><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name><name sortKey="Mcmahon, Bridget A" sort="Mcmahon, Bridget A" uniqKey="Mcmahon B" first="Bridget A" last="Mcmahon">Bridget A. Mcmahon</name><name sortKey="Min, Ji Young" sort="Min, Ji Young" uniqKey="Min J" first="Ji-Young" last="Min">Ji-Young Min</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><name sortKey="Thumar, Bhagvanji" sort="Thumar, Bhagvanji" uniqKey="Thumar B" first="Bhagvanji" last="Thumar">Bhagvanji Thumar</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Talaat, Kawsar R" sort="Talaat, Kawsar R" uniqKey="Talaat K" first="Kawsar R" last="Talaat">Kawsar R. Talaat</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22417012
|texte= An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22417012" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |